GenVec/US Gov HIV vacc contract renewed
US drug developer GenVec says that the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, has, for the second time, renewed its option period on its five-year, $52-million contract with the firm for the production of HIV vaccines.
GenVec will receive up to $3.8 million for the third year of activities. The firm says the funds will continue to support the development of new HIV vaccine candidates based on its proprietary adenovirus vector and production cell line technologies.
GenVec and the NIAID Vaccine Research Center have partnered on HIV vaccine development for several years under a Collaborative R&D Agreement. Under a separate contract, GenVec has produced adenovector-based HIV vaccines that have been tested in approximately 1,400 subjects in 16 NIAID-sponsored Phase I and Phase II clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze